DOMH - Dominari Holdings Inc.
NASDAQ
->
Healthcare
->
Biotechnology
New York,
United States
Type: Equity
DOMH price evolution
DOMH
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3.4 | $5.8 | $1.96 | $2.83 |
| Short term investments | ||||
| Net receivables | $0.28 | $0.96 | $1.96 | $3.18 |
| Inventory | ||||
| Total current assets | $24.76 | $28.77 | $25.36 | $28.14 |
| Long term investments | ||||
| Property, plant & equipment | $3.31 | $3.44 | $3.56 | $3.68 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $43.43 | $49.07 | $52.19 | $57.56 |
| Current liabilities | ||||
| Accounts payable | $1.29 | $0.94 | $0.84 | $1.04 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $2.42 | $3.9 | $1.6 | $1.61 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $5.16 | $6.71 | $4.53 | $4.63 |
| Shareholders' equity | ||||
| Retained earnings | -$224.53 | -$220.32 | -$214.2 | -$208.76 |
| Other shareholder equity | -$0 | -$0 | -$0 | -$0 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.83 | $33.2 | $69.8 | $2.7 |
| Short term investments | ||||
| Net receivables | $3.18 | $7.5 | $7 | |
| Inventory | ||||
| Total current assets | $28.14 | $50.7 | $90.9 | $27.7 |
| Long term investments | ||||
| Property, plant & equipment | $3.68 | $0.9 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $57.56 | $76.2 | $102.7 | $30.5 |
| Current liabilities | ||||
| Accounts payable | $1.04 | $0.4 | $0.4 | $0.6 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $1.61 | $1.8 | $1.1 | $0.9 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $4.63 | $2.5 | $1.1 | $0.9 |
| Shareholders' equity | ||||
| Retained earnings | -$208.76 | -$185.9 | -$163.8 | -$156.6 |
| Other shareholder equity | -$0 | |||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4.04 | $6.17 | $1.37 | $1 |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $7.24 | $8.91 | $4.17 | $6.85 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$0.59 | -$2.64 | -$1.72 | $1.93 |
| Net income | ||||
| Net income | -$4.21 | -$6.12 | -$5.44 | -$6.92 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.04 | |||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $23.84 | $14.35 | $9.44 | $6.55 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $2.13 | -$7.83 | $2.14 | -$5.81 |
| Net income | ||||
| Net income | -$22.88 | -$26.22 | -$7.17 | -$12.34 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $12.47 | $10.15 | $7.72 | -$7.17 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$0.94 | |||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $0.57 | $2.97 | -$0.88 | -$30.34 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$7.17 | -$14.6 | -$8.85 | -$24.96 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$0.94 | -$7.19 | $78.3 | $31.61 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$30.34 | -$32.39 | $62.85 | $2.63 |
News
|
10 Micro-Cap Healthcare Stocks Insiders Are Buying
Insider Monkey via Yahoo Finance
14 Apr 2024
|
Fundamentals
| Market cap | $6.84M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 6.28M |
| Revenue | $12.59M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$22.69M |
| Revenue Q/Q | 321.15% |
| Revenue Y/Y | 1.21K% |
| P/E ratio | -0.30 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.54 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.54 |
| EPS | -$3.61 |
|---|---|
| ROA | -44.87% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 10.25 |
| Quick ratio | N/A |